IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical (ICCM) has 4 years of Current Deferred Revenue data on file, last reported at $255000.0 in Q4 2025.

• Quarterly Current Deferred Revenue fell 23.65% year-over-year to $255000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $255000.0 (down 23.65% YoY) and the FY2025 annual result came in at $255000.0, down 23.65% from the prior year.
• Current Deferred Revenue retreated to $255000.0 in Q4 2025 per ICCM's latest filing, from $334000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $646000.0 in Q4 2022 and bottomed at $187000.0 in Q4 2023.
• The 4-year median for Current Deferred Revenue is $294500.0 (2024), against an average of $355500.0.
• The widest annual swing landed in 2023, when Current Deferred Revenue slumped 71.05%; it then soared 78.61% in 2024.
• Tracing ICCM's Current Deferred Revenue over 4 years: stood at $646000.0 in 2022, then tumbled by 71.05% to $187000.0 in 2023, then soared by 78.61% to $334000.0 in 2024, then slipped by 23.65% to $255000.0 in 2025.
• Per Business Quant, the three latest ICCM Current Deferred Revenue figures stand at $255000.0 (Q4 2025), $334000.0 (Q4 2024), and $187000.0 (Q4 2023).

Peer Comparison